These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38146679)

  • 1. Charles Brenton Huggins: A historical review of the Nobel laureate's pioneering discoveries.
    Benadada F; Saad F; Delouya G; Taussky D
    Cancer; 2024 Apr; 130(7):1019-1024. PubMed ID: 38146679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Charles Huggins made his Nobel prize winning discovery--in his own words: an historic audio recording. Interviewed by Willard Goodwin and Elmer Bell.
    Huggins C
    Prostate; 2012 Dec; 72(16):1718. PubMed ID: 22549876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remembering Charles B. Huggins' Nobel Prize for Hormonal Treatment of Prostatic Cancer at its 50th Anniversary.
    Hansson N; Moll F; Schultheiss D; Krischel M
    Eur Urol; 2016 Jun; 69(6):971-2. PubMed ID: 26838478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges.
    Glina S; Rivero MA; Morales A; Morgentaler A
    J Sex Med; 2010 Feb; 7(2 Pt 1):640-4. PubMed ID: 20492413
    [No Abstract]   [Full Text] [Related]  

  • 5. Endocrine treatment in prostate cancer.
    Denis LJ; Griffiths K
    Semin Surg Oncol; 2000; 18(1):52-74. PubMed ID: 10617897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal Therapy for Prostate Cancer.
    Desai K; McManus JM; Sharifi N
    Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies of androgen ablation therapy for metastatic prostate cancer.
    Wilson SS; Crawford ED
    Curr Pharm Des; 2006; 12(7):799-805. PubMed ID: 16515496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hormonotherapy for prostate cancer].
    Oishi K; Yoshida O
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2300-5. PubMed ID: 8259842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy for prostate cancer: what have we done with Charles Huggins' legacy?
    Tombal B
    Eur Urol; 2012 Jan; 61(1):26-8. PubMed ID: 21940097
    [No Abstract]   [Full Text] [Related]  

  • 10. [Nobel Prize of the year. II. Charles B. Huggins].
    Franksson C
    Lakartidningen; 1966 Oct; 63(43):4102-4. PubMed ID: 5343069
    [No Abstract]   [Full Text] [Related]  

  • 11. Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer.
    Morgentaler A
    J Sex Med; 2008 Aug; 5(8):1834-40. PubMed ID: 18547385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meaningful legacy: urologists as Nobel Prize laureates.
    Mouraviev V; Gleave ME
    Can J Urol; 2003 Feb; 10(1):1737-42. PubMed ID: 12625851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine therapy: where do we stand and where are we going?
    Schröder FH
    Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Intermittent and Continuous Androgen Deprivation Therapy in Prostate Cancer Patients: An Up-to-Date Meta-analysis for Urologists and Medical Providers.
    Becker B; Stroever S; Reddy A; de Riese WTW
    Urol Pract; 2023 Sep; 10(5):424-434. PubMed ID: 37505912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting androgen receptor signaling: a historical perspective.
    Davies AH; Zoubeidi A
    Endocr Relat Cancer; 2021 Jul; 28(8):T11-T18. PubMed ID: 34128829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
    Nishiyama T
    Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
    Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
    J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
    Denmeade SR; Isaacs JT
    Prostate; 2010 Oct; 70(14):1600-7. PubMed ID: 20607766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.